Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.

Esraa M EloseilyPeter WeiserCourtney B CrayneHilary HainesMelissa L MannionMatthew L StollTimothy BeukelmanT Prescott AtkinsonRandy Q Cron

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2019)

These findings suggest that anakinra appears to be effective in treating pediatric patients with non-malignancy-associated secondary HLH/MAS, especially when it is given early in the disease course and when administered to patients who have an underlying rheumatic disease.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
rheumatoid arthritis
prognostic factors
peritoneal dialysis
young adults